## Claims

1. An isolated antibody or antigen-binding fragment thereof, wherein the isolated antibody or antigen-binding fragment thereof immunospecifically binds to a *Staphylococcus aureus* alpha toxin polypeptide and includes:

(a) a VH CDR1 comprising the amino acid sequence of SEQ ID NO: 69;
(b) a VH CDR2 comprising the amino acid sequence of SEQ ID NO: 70;
(c) a VH CDR3 comprising the amino acid sequence of SEQ ID NO: 71;
(d) a VL CDR1 comprising the amino acid sequence of SEQ ID NO: 1;
(e) a VL CDR2 comprising the amino acid sequence of SEQ ID NO: 2, and
(f) a VL CDR3 comprising the amino acid sequence of SEQ ID NO: 68 .

2. An isolated antibody or antigen-binding fragment of claim 1 that comprises a heavy chain variable domain having at least 90% identity to the amino acid sequence of SEQ ID NO: 57, and a light chain variable domain having at least 90% identity to the amino acid sequence of SEQ ID NO: 58.

3. The antibody or antigen binding fragment of claim 2, wherein the VH and VL correspond to the amino acid sequences of SEQ ID NOs: 57 and 58.

4. The antibody or antigen binding fragment of any one of claims 1 to 3, wherein the isolated antibody or antigen-binding fragment thereof has one or more of the characteristics selected from the group consisting of:

(a) affinity constant ($K_D$) for alpha toxin of about 13 nM or less;
(b) binds to alpha toxin monomers, but does not inhibit binding of alpha toxin to alpha toxin receptor;
(c inhibits the formation of alpha toxin oligomers by at least 50%, 60%, 70%, 80%, 90%, or 95%;
(d) reduces alpha toxin cytolytic activity by at least 50%, 60%, 70%, 80%, 90%, or 95% (*e.g.*, as determined by cell lysis and hemolysis assays); and
(e) reduces cell infiltration and pro-inflammatory cytokine release (*e.g.*, in an animal pneumonia model).

5. A composition comprising the antibody or antigen binding fragment of any one of claims 1 to 4.

6. The composition according to claim 5, wherein the composition comprises an additional agent, wherein the additional agent is an antibiotic.

7. A kit, comprising

(a) an antibody or antigen binding fragment of any one of claims 1 to 4 or the composition of claim 5 or 6;

(b) instructions for using the composition or directions for obtaining instructions for using the composition.

8. An antibody or antigen binding fragment of any one of claims 1 to 4 or the composition of claim 5 or 6 for use in preventing, treating or managing pneumonia in a subject.

9. An antibody or antigen binding fragment of any one of claims 1 to 4 or the composition of claim 5 or 6 for use in preventing, treating or managing a skin infection condition in a subject.

10. An antibody or antigen binding fragment of any one of claims 1 to 4 or the composition of claim 5 or 6 for use in preventing, treating or managing pneumonia or a skin infection condition in a subject according to claim 8 or 9 by inhibiting the formation of *Staphylococcus aureus* alpha toxin oligomers by at least 50%, 60%, 70%, 80%, 90% or 95%.

11. An antibody or antigen binding fragment of any one of claims 1 to 4 that immunospecifically binds to a fragment of the *Staphylococcus aureus* alpha toxin of SEQ ID NO: 39.

12. An isolated antibody or antigen-binding fragment of claim 11, wherein the antibody or antigen-binding fragment thereof binds to a fragment comprising amino acids 261-272 of SEQ ID NO: 39 and/or amino acids 173-201 of SEQ ID NO: 39.

13. An isolated antibody or antigen-binding fragment of claim 12, wherein the antibody or antigen-binding fragment thereof binds to a fragment comprising amino acids 261-272 of SEQ ID NO: 39 and amino acids 173-201 of SEQ ID NO: 39

14. An isolated antibody or antigen-binding fragment of any one of claims 1 to 4, wherein the antibody or antigen-binding fragment thereof prevents alpha toxin heptamer formation, and wherein said antibody or antigen-binding fragment is in contact with the residues at positions T261, T263, N264, K266, K271, N177, W179, G180, P181, Y182, D183, D185, S186, W187, N188, P189, V190, Y191 and R200 of SEQ ID NO: 39.

15. The composition of claim 6, wherein the antibiotic is vancomycin.

16. An isolated antibody or antigen-binding fragment of any one of claims 11 to 14 for use in preventing, treating or managing pneumonia or a skin infection condition in a subject by inhibiting the formation of alpha toxin oligomers.

17. An isolated antibody or antigen-binding fragment according to any preceding claim which comprises a variant Fc region wherein the variant Fc region has the sequence of the Fc region of the isolated antibody or antigen-binding comprising the following sequence

EVQLVESGGGLVQPGGSLRLSCAASGFTFSSHDMHWVRQATGKGLEWVSGIGTAGD
TYYPDSVKGRFTISRENAKNSLYLQMNSLRAGDTAVYYCARDRYSPTGHYYGMDVWG
QGTTVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSG
VHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHT
CPPCPAPELLGGPSVFLFPPKPKDTLYITREPEVTCVWDVSHEDPEVKFNWYVDGVEV
HNAKTKPREEQYNSTYRWSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQP
REPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSD
GSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK

and

DIQMTQSPSTLSASVGDRVTITCRASQSISSWLAWYQQKPGKAPKLLIYKASSLESGVP
SRFSGSGSGTEFTLTISSLQPDDFATYYCKQYADYWTFGQGTKVEIKRTVAAPSVFIFP

PSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLS
STLTLSKADYEKHKVYACEV